Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US

被引：1
|
作者：
Aguiar, Pedro, Jr. [1 ]
De Mello, Ramon [2 ]
Tadokoro, Hakaru [1 ]
Babiker, Hani [3 ]
Gutierres, Barbara [4 ]
Lopes, Gilberto [5 ]
机构：
[1] Univ Fed Sao Paulo, Sao Paulo, Brazil
[2] Univ Algarve, Faro, Portugal
[3] Honor Hlth, Scottsdale, AZ USA
[4] Univ Paulista, Sao Paulo, Brazil
[5] Ctr Paulista, Oncol & Oncoclin Grp, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
biomarker; Immunotherapy; Cost of Care; Access;
D O I：
10.1016/j.jtho.2016.11.324
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA17.01
引用
收藏
页码：S308 / S308
页数：1
相关论文
共 50 条
  • [41] Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
    Chen, Jing
    Alduais, Yaser
    Chen, Baoan
    CELL TRANSPLANTATION, 2021, 30
  • [42] THE BUDGET IMPACT OF INTRODUCING A PD-L1 ASSAY TO SELECT PATIENTS WITH METASTATIC NSCLC WHO ARE POTENTIAL CANDIDATES FOR TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS
    Sheppard, B.
    Ahlsten, M.
    Paolini, D.
    Xenakis, J.
    Zhang, W.
    VALUE IN HEALTH, 2017, 20 (09) : A576 - A576
  • [43] The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
    Wang, Qingshui
    Lin, Wei
    Tang, Xiaoqiong
    Li, Suhuan
    Guo, Libin
    Lin, Yao
    Kwok, Hang Fai
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (12)
  • [44] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
    Wang, Dongxu
    Lin, Jianzhen
    Yang, Xu
    Long, Junyu
    Bai, Yi
    Yang, Xiaobo
    Mao, Yilei
    Sang, Xinting
    Seery, Samuel
    Zhao, Haitao
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [45] Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
    Aden, Durre
    Zaheer, Samreen
    Sureka, Niti
    Trisal, Monal
    Chaurasia, Jai Kumar
    Zaheer, Sufian
    PATHOLOGY RESEARCH AND PRACTICE, 2025, 269
  • [46] Covalent small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint
    Maslanka, A.
    Kitel, R.
    Konopka, J.
    Skalniak, L.
    FEBS OPEN BIO, 2024, 14 : 329 - 330
  • [47] PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
    Caccese, Mario
    Indraccolo, Stefano
    Zagonel, Vittorina
    Lombardi, Giuseppe
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 135 : 128 - 134
  • [48] Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas
    Ribatti, Domenico
    Cazzato, Gerardo
    Tamma, Roberto
    Annese, Tiziana
    Ingravallo, Giuseppe
    Specchia, Giorgina
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [49] The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
    Mahoney, Kathleen M.
    Freeman, Gordon J.
    McDermott, David F.
    CLINICAL THERAPEUTICS, 2015, 37 (04) : 764 - 782
  • [50] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
    Dongxu Wang
    Jianzhen Lin
    Xu Yang
    Junyu Long
    Yi Bai
    Xiaobo Yang
    Yilei Mao
    Xinting Sang
    Samuel Seery
    Haitao Zhao
    Journal of Hematology & Oncology, 12
12345